Locations:
Min Investment:
Max Investment:
Target Investment:
Total Funding: $110M
Total Funding: $42M
Total Funding: $31M
Total Funding: $21M
Total Funding: $5M
Total Funding:
Total Funding: $620M
Total Funding: $250M
Total Funding: $140M
Total Funding: $3M
2018
2018
2009
Invited lectures on Venture Capital investing in life sciences.
2012 - 2018
2012 - 2018
Member of the Board of Trustees for the International Center for Tropical Agriculture in Cali, Colombia. The center focuses on sustainable agriculture with an emphasis on rice, cassava and bean. There is also a major focus on soil quality and the impacts of climate change on agriculture.
2012 - 2018
2012 - 2018
Leading Monsanto's corporate venture capital group to invest in technology impacting food, feed, fuel and farms.
2008 - 2012
2008 - 2012
Chromatin is a leading agricultural biotechnology developing grain, forage and sweet sorghum as a low water use, sustainable feedstock for bioprocessing.
2003 - 2011
2003 - 2011
Venture Partner, Dec. 2011-2012 Managing Director, January 2006-Dec 2011. General Partner (ret.), Burrill Life Sciences Capital Fund IIII Malaysian Life Sciences Capital Fund Board of Directors, Burrill Malaysia Burrill Brazil Fund Investment Committee (2006-2011) Entrepreneur-in-Residence (2003-2005)
2003 - 2006
2003 - 2006
Founder/CEO and President. Oct 2003-Feb 2006 • Co-founded with Dr. Bruce Hammock (Distinguished Professor UC Davis) as a cardiovascular drug development company.
1998 - 2003
1998 - 2003
• Paradigm Genetics Inc.-a platform genomic technology company focused on Ag-biotechnology and biomarkers for healthcare. Investors: Polaris, Intersouth, Burrill, . Founded 1997, IPO-NASDAQ-May 2000. (Market Cap $600M-$10M). Changed name to Icoria-2003. Sold in 2004 to Monsanto and Clinical Data.
1988 - 2000
1988 - 2000
Adjunct Professor, 9/01-present Full Professor, 9/98-9/01 Associate Professor 9/93-9/98 Assistant Professor 9/89-9/93 Visiting Assistant Professor 9/88-9/89
1993 - 1999
1993 - 1999
•Restructured the journal including Editorial content, review Board, to become the leading journal in fungal genetics, physiology, pathology and biotechnology. Recognized by Academic Press for Editorial Achievement.